BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16005602)

  • 1. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
    Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
    Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
    van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
    J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
    Ardern-Jones A; Kenen R; Eeles R
    Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy.
    Murphy RX; Adkinson JM; Namey T; Eid S; Bleznak A
    Ann Plast Surg; 2010 May; 64(5):684-7. PubMed ID: 20395792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
    Esplen MJ; Hunter J; Leszcz M; Warner E; Narod S; Metcalfe K; Glendon G; Butler K; Liede A; Young MA; Kieffer S; DiProspero L; Irwin E; Wong J
    Cancer; 2004 Nov; 101(10):2327-40. PubMed ID: 15478194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening and follow-up of the patient at high risk for breast cancer.
    Willey SC; Cocilovo C
    Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.
    van Oostrom I; Meijers-Heijboer H; Lodder LN; Duivenvoorden HJ; van Gool AR; Seynaeve C; van der Meer CA; Klijn JG; van Geel BN; Burger CW; Wladimiroff JW; Tibben A
    J Clin Oncol; 2003 Oct; 21(20):3867-74. PubMed ID: 14551306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Numerous high-risk epithelial lesions in familial breast cancer.
    Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
    Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer.
    Haroun I; Graham T; Poll A; Sun P; Hill K; Weitzner E; Narod S; Warner E
    Breast; 2011 Jun; 20(3):254-8. PubMed ID: 21306899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk reducing mastectomy: outcomes in 10 European centres.
    Evans DG; Baildam AD; Anderson E; Brain A; Shenton A; Vasen HF; Eccles D; Lucassen A; Pichert G; Hamed H; Moller P; Maehle L; Morrison PJ; Stoppat-Lyonnet D; Gregory H; Smyth E; Niederacher D; Nestle-Krämling C; Campbell J; Hopwood P; Lalloo F; Howell A
    J Med Genet; 2009 Apr; 46(4):254-8. PubMed ID: 18996907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
    Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
    Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preventive surgical prcedures for inherited risk of breast cancer].
    Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
    Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.